Spruce Biosciences, Inc.
News
Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Business Wire Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant...\n more…
Short Interest in Spruce Biosciences, Inc. (NASDAQ:SPRB) Grows By 52.1%
Ticker Report Spruce Biosciences, Inc. (NASDAQ:SPRB - Get Free Report) saw a large increase in short interest in August. As of August 15th, there was short interest totalling 205,400 shares, an increase of 52.1...\n more…
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives $5.00 Consensus Target Price from Brokerages
Zolmax Spruce Biosciences, Inc. (NASDAQ:SPRB - Get Free Report) has been given a consensus recommendation of "Hold" by the eight brokerages that are presently covering the firm, MarketBeat Ratings reports...\n more…
Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Consensus Recommendation of "Hold" by Brokerages
Ticker Report Spruce Biosciences, Inc. (NASDAQ:SPRB - Get Free Report) has earned a consensus rating of "Hold" from the eight research firms that are presently covering the company, Marketbeat reports. Six...\n more…
Spruce Biosciences, Inc. to Post Q3 2024 Earnings of ($0.24) Per Share, HC Wainwright Forecasts (NASDAQ:SPRB)
Ticker Report Spruce Biosciences, Inc. (NASDAQ:SPRB - Free Report) - HC Wainwright increased their Q3 2024 earnings per share (EPS) estimates for Spruce Biosciences in a research report issued to clients and...\n more…